

Lead Product(s) : Nitroaspirin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Details : Ncx-4016 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intermittent Claudication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2010
Lead Product(s) : Nitroaspirin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
